This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Freedman DS, Williamson DF, Gunter EW, Byers T Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic follow-up study Am J Epidemiol 1995 141 637–644
Culleton BF, Larson MG, Kannel WB, Levy D Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study Ann Intern Med 1999 131 7–13
Nakashima M, Uematsu T, Kosuge K, Kanamaru M Pilot Study of the uricosuric effect of DuP-753, a new angotensin II receptor antagonist, in healthy subjects Eur J Clin Pharmacol 1992 42 333–335
Tykarski A et alComparison of the effects of angiotensin II antagonists and ACE inhibitors on renal handling of uric acid in hypertensivepatients (abstract) European Renal Association, European Dialysis and Transplant Association Annual Congress, 1999, Abstract Book p 78
Gonzalez-Ortiz M, Mora-Martinez JM, Martinez-Abundis E, Balcazar-Munoz BR Effect of valsartan on renal handling of uric acid in healthy subjects J Nephrol 2000 13 126–128
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sayin, T., Döven, O., Akyürek, Ö. et al. Neutral effect of valsartan on serum uric acid and renal function tests. J Hum Hypertens 15, 435–436 (2001). https://doi.org/10.1038/sj.jhh.1001188
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001188
This article is cited by
-
Do angiotensin II antagonists provide benefits beyond blood pressure reduction?
Advances in Therapy (2005)